The prognosis of younger patients with intermediate/high risk acute myelogenous leukemia (AML) or high-risk myelodysplastic syndromes (MDS) remains unsatisfactory. [1] [2] [3] [4] Clofarabine is a purine nucleoside analog that is highly active as a single agent in AML. 5 Furthermore, synergy between clofarabine and Ara-C has been demonstrated in vitro 6 and in AML patients. [6] [7] [8] We have recently reported the results of the randomized phase I part of the EORTC/GIMEMA-AML-14A trial and identified clofarabine at 10 mg/m 2 /day on days 2, 4, 6, 8 and 10 as the maximum tolerated dose (given either in a 1-hour infusion or as push injection) in combination with Ara-C and idarubicin. 9 We decided to administer clofarabine on these five days because we hypothesized that the synergy between clofarabine and Ara-C would be more effective when clofarabine was present in the leukemic cells during the entire period of Ara-C administration. Furthermore, we hypothesized that push injections of clofarabine might result in higher clofarabine peak levels than a 1-hour infusion schedule, leading to a better interaction with Ara-C and more pronounced anti-leukemic effects. We report the final results of the combined phase haematologica 2017; 102:e47 I and II parts of the trial. EORTC/GIMEMA-AML-14A is an open label randomized 2-arm multicenter trial with a sequential phase I-II design (clinicaltrials.gov identifier: 00838240). The protocol was approved by the EORTC Protocol Review Committee and by the Ethical Committee of each participating center. The main objective of the phase II part of the trial was to explore the anti-leukemic activity of the aforementioned phase I selected dosage schedules of clofarabine given either as a 1-hour intravenous (iv) infusion (Arm A) or as a push injection (Arm B) over ten minutes. The primary end point was the complete remission (CR)/CR with incomplete blood count recovery (CRi) rate after 1 or 2 induction cycles. The aim was to determine whether, in each treatment group, the true CR/CRi rate was more than 65% or not. Thus, for each of the arms A and B, the regimen was considered as active and feasible if 23 or more of 30 (76.7%) patients achieved a CR/CRi (see Online Supplementary Appendix for detailed study design and methods of statistical analyses). Secondary end points included toxicity, overall survival (OS) from inclusion, OS from CR/CRi, relapse-free survival (RFS) from CR/CRi, and incidences of relapse and of death in CR/CRi. /L), blast crisis chronic myeloid leukemia or AML supervening a myeloproliferative disorder, central nervous system leukemia, evidence of severe concurrent cardiac, pulmonary, and neurological disorder, and uncontrolled infection.
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Clofarabine was administered at 10 mg/m 2 on days 2, 4, 6, 8 and 10 either as a 1-hour infusion (Arm A) or as a push injection (Arm B). Ara-C was administered at 100 mg/m 2 /day on days 1-10 as a continuous infusion, while idarubicin was given at 10 mg/m 2 /day on days 1, 3, and 5 as a 5-minute iv injection. A second identical course of induction chemotherapy was given in case of a partial response (PR). One cycle of consolidation chemotherapy consisting of Ara-C (500 mg/m 2 every 12 hours as a 2-hour iv infusion on days 1-6) and idarubicin (10 mg/m 2 /day on days 4, 5 and 6) was administered in patients in both arms who achieved a CR/CRi. Post-consolidation treatment was left at the discretion of the local principal investigator, but it was recommended that the consolidation phase was followed by allogeneic hematopoietic cell transplantation (HCT) for patients haematologica 2017; 102:e48 LETTERS TO THE EDITOR Figure 1 . Overall survival (A), relapse-free survival from complete remission (CR) (B), cumulative incidence of relapse from CR (C) and cumulative incidence of death in CR (D) in the two arms.
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with an HLA-identical related donor or for patients with very high-risk cytogenetics who had an HLA-compatible related or unrelated donor, or an autologous HCT in patients who were not candidates for allogeneic HCT.
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A total of 64 patients (12 in the phase I part and 52 in the phase II part of the study) were randomized at the dosage of clofarabine of 10 mg/m 2 /day (Online Supplementary Figure S1 ). Two patients were excluded because they did not meet the inclusion criteria. Among the remaining 62 patients, 41 had AML not otherwise specified, 11 AML with multilineage dysplasia, 5 therapyrelated AML while 5 patients were diagnosed with MDS-RAEB2. Median age was 49.5 (range 20-60) years.
Baseline characteristics were generally well balanced between the two arms (Table 1) .
After one induction course, the CR/CRi rates were 26 of 31 patients in arm A (84%) versus 25 of 31 patients in arm B (80%) ( Table 2 ). The CR/CRi rate after 1 or 2 induction courses was 84% (95%CI: 66%-95%), in both arms, higher than the protocol-defined efficacy (>65%) ( Table 2) . Interestingly, combining the results from both arms, the CR/CRi rate after 1 or 2 courses of induction was similar in patients with very high-risk cytogenetics [11 of 13 patients (84.6%)], and in patients with normal or high-risk cytogenetics [38 of 46 patients (82.6%)]. These results are in the same range as those observed in haematologica 2017; 102:e49 Evaluation of response was scheduled around day 31 after the start of the induction course. CR was defined as less than 5% marrow blasts and recovery of normal hematopoiesis with a neutrophil count ≥ 1x10 9 /L and a platelet count ≥ 100x10 9 /L in addition to disappearance of all clinical, laboratory, or radiological evidence of disease. The term incomplete CR (CRi) was used to define patients who met all CR criteria, but had neutrophil counts between 0.5 and 1.0x10 9 /L and/or platelet counts between 50 and 100x10 9 /L. Finally, partial remission (PR) was defined as 5%-25% blast cells in the bone marrow and a reduction of at least 50% of blasts in the bone marrow, irrespective of count recovery. b Adverse events were graded with Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 scoring system (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf).
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two recent phase II studies investigating the efficacy of higher dosages of clofarabine combined with AraC (and idarubicin) as remission induction regimen for younger AML patients.
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